公司資料
Moleculin Biotech, Inc. 股價、新聞與催化劑
- 股票代碼:
- MBRX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.61 USD (-0.85%)
收盤價
最後更新: 2026年8月17日
13.1M USD
市值
股價為何變動
Following the latest company update, “Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial”, MBRX closed up 7.16% at $0.6122 on Aug 14, 2026. The move occurred in the trading session associated with this clinical readout update.
公司概覽
Late-Stage Oncology Pipeline
Moleculin Biotech is a clinical-stage company developing treatments for difficult-to-treat cancers and viral diseases. Its portfolio centers on Annamycin in acute myeloid leukemia, supported by earlier-stage programs targeting oncogenic transcription and tumor metabolism.
Annamycin
Annamycin is a next-generation anthracycline designed to avoid multidrug-resistance mechanisms and reduce the cardiotoxicity associated with conventional anthracyclines. The candidate is being developed in relapsed or refractory AML and has also been studied in soft-tissue sarcoma metastatic to the lungs.
MIRACLE Program
MIRACLE is an adaptive pivotal Phase 2/3 study evaluating Annamycin with cytarabine, a regimen referred to as AnnAraC, in second-line relapsed or refractory AML. Part A is designed to enroll approximately 90 patients and identify the dose and regimen to carry into the confirmatory portion of the study.
Additional Development Programs
The pipeline also includes WP1066, a modulator of p-STAT3 and other oncogenic transcription factors under evaluation in brain and pancreatic cancers, and WP1122, a metabolic antitumor and antiviral platform. These programs provide development opportunities beyond Annamycin and hematologic malignancies.
未來催化劑
- Completion of enrollment in Part A of the MIRACLE trial in September 2026.
- Initiation of an Atlantic Health investigator-sponsored Annamycin study in pancreatic cancer in the second half of 2026.
- Unblinding and efficacy readout from MIRACLE Part A between December 2026 and February 2027.
- Initiation of MIRACLE Part B in the first half of 2027.
- Planned start of a rolling NDA submission for Annamycin under an accelerated-approval pathway in 2028.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。